Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26160021 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL7400688 | 0.83 | AGTR2 (0.46) | SMN1; SMN2NPC1RAB9AAGTR2SIGMAR1 | |
| SCHEMBL21538530 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19ELANE | |
| SCHEMBL10949793 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL30142140 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL77520 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL809534 | 0.78 | PREP (0.57) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14646609 | 0.77 | NPC1 (0.60) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL13198885 | 0.77 | NPC1 (0.60) | SMN1; SMN2NPC1RAB9ASIGMAR1TMEM97 | |
| SCHEMBL29059905 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5753659-A | ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, | ZENECA LIMITED (GB) | 1998-05-19 | — | — | US | disclosed |
| US-5750754-A | TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS | ZENECA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |